Business Wire

CA-CONVIVA

9.9.2022 12:21:36 CEST | Business Wire | Press release

Share
Worldwide Streaming Market Achieves Double-digit Growth in Q2 2022; Smart TVs and Roku Dominate Global Viewing According to Conviva

Conviva, the global streaming analytics platform, released today the results of its quarterly State of Streaming Report, which shows continued growth in the global streaming market, including gains of (14%) in the second quarter of 2022 as compared to Q2 2021. Asia and Latin America saw the most growth — 90% and 70%, respectively — while North America, the most mature streaming market in the world, also grew 5% year over year.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220909005099/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Conviva's State of Streaming Report Q2 2022 (Graphic: Business Wire)

As the global streaming industry matures, streaming success is getting more complicated. Device fragmentation is growing, and viewers’ quality expectations continue rising in concert with an ad-supported streaming world. Streaming publishers are challenged to deliver a consistent and positive experience. Whether in Africa using an Android phone or in Texas on a Smart TV – viewers expect a quality picture, instant access to content and zero glitches.

“The race is on to see which publishers will meet these expectations, including providing the best experience when it’s most important,” said Keith Zubchevich, President and CEO, Conviva. “Those who do will quickly eclipse the competition. Most importantly, those who make it a priority to obtain real-time actionable insights about their customers’ (real-world experiences) will undoubtedly separate the leaders from the pack,” added Zubchevich.

Key Findings

Bitrates are Rising

Conviva found bitrate rose globally in Q2 2022 across all screen types and devices, but often at the expense of other quality metrics. For example, Smart TVs saw the largest increase in bitrate of all screen types, up 15.1% year over year. However, to provide this more high-definition experience, Smart TVs saw noticeable increases in video start failures, video start time and buffering. Conversely, PlayStation and Roku were the only big screen devices to both decrease video start times (down 10.7% and 12% respectively) and increase bitrate (up 4.6% and 12.9% respectively).

Big Screens – and Roku – Remain on Top

Roku continued to hold the top spot among big screen devices (big screens include connected TVs, Smart TVs and gaming consoles), holding nearly steady at 30.5% of viewing time, down less than one percent as compared to Q2 2021 with Amazon Fire TV coming in second with 16% of big screen viewing time. Samsung TV (13.7%), Android TV (7.8%) and LG TV (7.3%) rounded out the top five devices for big screen viewing time. Chromecast, Xbox and PlayStation all saw a decrease in share as compared to the previous year.

Android vs iPhone Streaming Showdown

To date, the iPhone has been the primary device for mobile streaming, especially in North America. In Q2 2022 the gap closed, with iPhone and Android phones capturing nearly identical global market share, 35.8% vs 33.2% respectively. In addition, Android phones outpaced the iPhone by 10% in YoY growth in streaming viewing hours. In Apple’s favor is its quality — as the iPhone currently beats Android phones in every quality category. As streaming publishers expand into newer, less mature streaming markets outside of North America, optimizing the streaming experience for the android mobile device market will be of increasing importance.

Methodology

Conviva’s State of Streaming series is the largest cross-platform comparison of streaming data measuring ongoing, real-time, sessionized streaming data at Internet-scale.

Data analyzed for the Q2 2022 State of Streaming report was primarily collected from Conviva’s unique proprietary sensor technology. Currently embedded in 3.3 billion streaming video applications, it measures more than 500 million unique viewers watching 180 billion streams per year and nearly 2 trillion real-time transactions per day across more than 180 countries. The Internet-scale census-measurement is deployed from a full-stack censor that is not sampled, but validated, cleaned, enriched, standardized and sessionized. Continuous, real-time monitoring sessionizes streaming events, state timelines and meta data into viewer-led sessions. This more accurately reflects viewers’ real-world experiences.

The social media data, collected from the Streaming Publishers leaderboard list within Conviva Social Insights, consists of data from 100 accounts, over 7,500 million posts, and over 30 million engagements across Facebook, Instagram, Twitter, TikTok and YouTube between Q2 2021 and Q2 2022.

Year-over-year comparisons were normalized at the customer level for accurate representations of industry growth.

Get a copy of Conviva’s Q2 State of Streaming Report

About Conviva

Conviva is the only global streaming analytics platform for big data that collects, standardizes, and puts trillions of streaming data points in context, in real time. With Conviva, streaming businesses can understand real-world human experiences within seconds of observation and take action to grow their business ahead of the competition.

The Conviva platform provides comprehensive, continuous, census-level measurement through real-time, server side sessionization at scale. It includes first-of-its kind-innovations like time-state analytics and AI automated data modeling. Using a single full stack sensor at the source, coupled with a single big data pipeline, Conviva’s 60+ patent platform enables marketers, advertisers, tech ops, engineering and customer care teams to acquire, engage, monetize and retain their audiences. Conviva is dedicated to supporting brands like DAZN, Disney+, Hulu, Paramount+, Peacock, Sky, Sling TV, TED and WarnerMedia as they unlock incredible opportunity with streaming analytics. To learn more, visit www.conviva.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220909005099/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro

Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a

Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release

Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere

The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release

The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e

Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release

Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye